Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 5/20 | 0.67 |
| ▸ | HTR2A | P28223 | 4/20 | 0.67 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.67 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.65 |
| ▸ | GFER | P55789 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.58 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | MMP9 | P14780 | 1/20 | 0.56 |
| ▸ | MMP8 | P22894 | 1/20 | 0.56 |
| ▸ | MMP14 | P50281 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 2/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16433301 | 0.95 | SLC6A4 (0.65) | SLC6A4HTR2ATRPM8GPR84GFER | |
| SCHEMBL11162502 | 0.90 | HTR2A (0.71) | SLC6A4HTR2ATRPM8GPR84GFER | |
| SCHEMBL16540596 | 0.87 | SLC6A4 (0.67) | SLC6A4HTR2ATRPM8GPR84GFER | |
| SCHEMBL15676249 | 0.85 | HTR2A (0.69) | SLC6A4HTR2ATRPM8GPR84GFER | |
| SCHEMBL892282 | 0.84 | SLC6A4 (0.67) | SLC6A4HTR2ATRPM8GPR84GFER | |
| SCHEMBL8808469 | 0.84 | SLC6A4 (0.67) | SLC6A4HTR2ATRPM8GPR84GFER | |
| SCHEMBL892989 | 0.84 | HTR2A (0.82) | SLC6A4HTR2ATRPM8GPR84GFER | |
| SCHEMBL28117188 | 0.84 | SLC6A4 (0.71) | SLC6A4HTR2ATRPM8GPR84GFER | |
| SCHEMBL7599108 | 0.83 | GPR84 (0.73) | SLC6A4HTR2ATRPM8GPR84GFER | |
| SCHEMBL7466733 | 0.83 | SLC6A4 (0.69) | SLC6A4HTR2ATRPM8GPR84GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110511174-B | Indolylalkyl piperazine compound and application thereof | 复旦大学 | 2023-03-28 | — | — | CN | disclosed |
| EP-3027607-B1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2020-08-26 | — | — | EP | disclosed |
| EP-3190109-B1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | UNIV LEUVEN KATH (BE) | 2020-02-19 | — | — | EP | disclosed |
| CN-110511174-A | A kind of indolyl piperazine compounds and its application | UNIV FUDAN | 2019-11-29 | — | — | CN | disclosed |
| US-20190054068-A1 | Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases | REMYND (BE) | 2019-02-21 | — | — | US | disclosed |
| US-10117850-B2 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2018-11-06 | — | — | US | disclosed |
| EP-3190109-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Katholieke Universiteit Leuven (BE) | 2017-07-12 | — | — | EP | disclosed |
| EP-2651888-B1 | N-((1H-indol-3-yl)-alkyl)-4-benzyl)benzamide and N-((1H-pyrrolo[2,3-b]pyridin-3-yl)-alkyl)-4-benzyl)benzamide derivatives as alpha synuclein aggregation inhibitors for the treatment of neurodegenerative disorders | UNIV LEUVEN KATH (BE) | 2017-05-17 | — | — | EP | disclosed |
| US-9598401-B2 | Substituted heteroaryl compounds and methods of use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-03-21 | — | — | US | disclosed |
| EP-2440550-B1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | UNIV LEUVEN KATH (BE) | 2017-03-15 | — | — | EP | disclosed |
| WO-2010142801-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2010-12-16 | — | — | WO | disclosed |
| EP-1827427-B1 | ARYLOXYETHYLAMINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARM BV (NL) | 2008-07-23 | — | — | EP | disclosed |
| US-20070142397-A2 | PHENYPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMECEUTICALS B.V. (NL) | 2007-06-21 | — | — | US | disclosed |
| WO-2006061379-A1 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-06-15 | — | — | WO | disclosed |
| WO-2005034837-A2 | 7H-IMIDAZO [1,2-α] PYRAZIN-8-ONE COMPOUNDS AS ION CHANNEL MODULATORS | CARDIOME PHARMA CORPORATION (US) | 2005-04-21 | — | — | WO | disclosed |
| EP-0464604-B1 | 1-Indolylalkyl-4-(alkoxy-pyrimidinyl)piperazines | BRISTOL MYERS SQUIBB CO (US) | 1995-03-29 | — | — | EP | disclosed |
| EP-0464558-B1 | Antimigraine alkoxypyrimidine derivatives | BRISTOL MYERS SQUIBB CO (US) | 1994-12-28 | — | — | EP | disclosed |
| EP-0464604-A2 | 1-Indolylalkyl-4-(alkoxy-pyrimidinyl)piperazines | Bristol-Myers Squibb Company (US) | 1992-01-08 | — | — | EP | disclosed |
| EP-0464558-A1 | Antimigraine alkoxypyrimidine derivatives | Bristol-Myers Squibb Company (US) | 1992-01-08 | — | — | EP | disclosed |
| US-5077293-A | Antidepressants | BRISTOL-MYERS SQUIBB CO. (US) | 1991-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190054068-A1 | Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases | SNCA, MAPT, NLN | SLC6A4 156/4885HTR2A 106/4885TRPM8 1477/4885 |
| US-10117850-B2 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | SNCA, MAPT, NLN | SLC6A4 150/4885HTR2A 112/4885TRPM8 1521/4885 |
| US-20070142397-A2 | PHENYPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | HTR2C, HTR2A, HTR5A | SLC6A4 33/4885HTR2A 2/4885TRPM8 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.